As gene therapy for MPS IIID, Roca et al. (2017) administered 5 × 1010 vg of AAV9 vector expressing murine Gns into 2-month-old Gns−/− mice through cisterna magna injection. This evidence concerns the gene GNS and mucopolysaccharidosis type 3D.